文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤

肺转移瘤按原发组织学类型的放射敏感性及基因组调整放疗剂量的意义

Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose.
PubMed 文献 · J Thorac Oncol · 2018-05-05

该研究利用经验证的10基因放射敏感性指数(RSI)检测138个肺转移灶,并按原发组织学类型比较放射敏感性,同时用基因组调整放疗剂量(GARD)建模。结果显示不同组织学类型间RSI存在显著差异(p=0.002),临床队列中放射抵抗型与敏感型肺SBRT后局部控制率在12/24个月分别为92%/87%与100%(p=0.02)。

要点

  • 肺转移瘤的放射敏感性随原发组织学类型显著不同,RSI中位值从子宫内膜腺癌0.49至乳腺腺癌0.29。
  • 按放射抵抗递减排序:子宫内膜腺癌、软组织肉瘤、黑色素瘤、直肠腺癌、肾细胞癌、头颈鳞癌、结肠腺癌、乳腺腺癌。
  • 临床队列中放射抵抗型与敏感型肺SBRT后12/24个月局部控制率分别为92%/87%与100%(p=0.02)。

核心结论

  • 肺转移瘤的放射敏感性按原发组织学类型存在显著差异,原发组织学类型可能是选择肺SBRT剂量时需额外考虑的因素,剂量个体化可行。

研究设计与样本

  • 研究样本来自前瞻性观察protocol的组织库,共138个独特肺转移灶;采用10基因RSI检测并结合GARD建模。
  • 临床相关性队列纳入105例患者、137个肺转移灶,均在本机构接受SBRT。

主要发现

  • 不同组织学类型肺转移灶的RSI存在显著差异(p=0.002)。
  • 按放射抵抗递减,中位RSI为子宫内膜腺癌0.49、软组织肉瘤0.47、黑色素瘤0.44、直肠腺癌0.43、肾细胞癌0.33、头颈鳞癌0.33、结肠腺癌0.32、乳腺腺癌0.29。
  • 临床队列中放射抵抗型与敏感型组织学类型肺SBRT后12个月和24个月局部控制的Kaplan-Meier率分别为92%/87%与100%(p=0.02)。

关键数值与推荐

  • RSI中位值:子宫内膜腺癌0.49、软组织肉瘤0.47、黑色素瘤0.44、直肠腺癌0.43、肾细胞癌0.33、头颈鳞癌0.33、结肠腺癌0.32、乳腺腺癌0.29(p=0.002)。
  • 临床队列放射抵抗型与敏感型12/24个月局部控制率分别为92%/87%与100%(p=0.02)。

临床怎么用

  • 肺转移瘤行SBRT剂量选择时,除常规因素外可参考原发组织学类型的放射敏感性差异。
  • 基于RSI/GARD建模优化生物有效剂量以实现局部控制个体化,尚需进一步验证。

局限性

  • 临床相关性队列为单机构105例患者137个肺转移灶,样本量有限。
  • GARD建模所得优化局部控制的生物有效剂量为模型推导,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We assessed the radiosensitivity of lung metastases on the basis of primary histologic type by using a validated gene signature and model lung metastases for the gnomically adjusted radiation dose (GARD). METHODS: Tissue samples were identified from our prospective observational protocol. The radiosensitivity index (RSI) 10-gene assay was run on samples and calculated alongside the GARD by using the previously published algorithms. A cohort of 105 patients with 137 lung metastases treated with stereotactic body radiation therapy (SBRT) at our institution was used for clinical correlation. RESULTS: A total of 138 unique metastatic lung lesions from our institution's tissue biorepository were identified for inclusion. There were significant differences in the RSI of lung metastases on the basis of histology. In order of decreasing radioresistance, the median RSIs for the various histologic types of cancer were endometrial adenocarcinoma (0.49), soft-tissue sarcoma (0.47), melanoma (0.44), rectal adenocarcinoma (0.43), renal cell carcinoma (0.33), head and neck squamous cell cancer (0.33), colon adenocarcinoma (0.32), and breast adenocarcinoma (0.29) (p = 0.002). We modeled the GARD for these samples and identified the biologically effective dose necessary to optimize local control. The 12- and 24-month Kaplan-Meier rates of local control for radioresistant versus radiosensitive histologic types from our clinical correlation cohort after lung SBRT were 92%/87% and 100%, respectively (p = 0.02). CONCLUSIONS: In this analysis, we have noted significant differences in radiosensitivity on the basis of primary histologic type of lung metastases and have modeled the biologically effective dose necessary to optimize local control. This study suggests that primary histologic type may be an additional factor to consider in selection of SBRT dose to the lung and that dose personalization may be feasible.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ahmed KA, Scott JG, Arrington JA, et al. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. J Thorac Oncol. 2018. PMID: 29733909. doi:10.1016/j.jtho.2018.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。